NCT06239220 - PD-L1 t-haNK, N-803 IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 16, 2024

Primary Completion Date

July 31, 2026

Study Completion Date

January 31, 2027

Conditions

Head and Neck CancerHead and Neck Squamous Cell CarcinomaMetastatic Head and Neck CancerRecurrent Head and Neck CancerMetastatic Head-and-neck Squamous-cell CarcinomaRecurrent Head and Neck Squamous Cell Carcinoma

Interventions

BIOLOGICAL

PD-L1 t-haNK

Allogeneic, stable, clonal natural killer cell line product, via intravenous infusion (into the vein) per protocol.

DRUG

Cetuximab

Epidermal growth factor receptor, via intravenous (into the vein) infusion per institutional standard of care.

BIOLOGICAL

N-803

Recombinant human superagonist, via subcutaneous injection (under the skin) per protocol.

Trial Locations (2)

02115

RECRUITING

Brigham and Women's Hospital, Boston

RECRUITING

Dana Farber Cancer Institute, Boston